Periactin (Cyproheptadine) is a first‑generation H1‑receptor antagonist that also blocks serotonin receptors, giving it both antihistamine and appetite‑stimulating properties. It’s been on the market since the 1960s and is prescribed for seasonal allergies, chronic urticaria, and to boost appetite in children or adults with low weight. Because it hits multiple receptors, its side‑effect profile differs from newer, more selective antihistamines.
Cyproheptadine binds tightly to H1 histamine receptors, preventing histamine‑induced itching, sneezing, and vasodilation. Simultaneously, it antagonizes 5‑HT2 serotonin receptors, which modulates appetite pathways in the hypothalamus. This dual action is why it’s unique among antihistamines.
Its metabolism is primarily hepatic via the CYP3A4 enzyme, producing inactive metabolites excreted in urine. The half‑life averages 8‑12hours, allowing once‑ or twice‑daily dosing.
Maximum daily dose should not exceed 20mg for adults to limit sedation and anticholinergic effects.
Because Periactin crosses the blood‑brain barrier, central side effects are prominent:
Contraindications include glaucoma, urinary retention, and known hypersensitivity. Caution is advised in pregnancy (Category B) and lactation-small amounts pass into breast milk.
When weighing options, consider the primary therapeutic goal.
Attribute | Periactin (Cyproheptadine) | Cetirizine | Loratadine | Megestrol acetate |
---|---|---|---|---|
Primary action | H1 + 5‑HT2 antagonist (antihistamine & appetite stimulant) | Selective H1 antagonist | Selective H1 antagonist | Progesterone analogue, strong appetite stimulant |
Onset (allergy relief) | 30‑60min | 1hour | 1‑2hours | 2‑3hours (weight gain effect) |
Sedation risk | High (30‑40%) | Low (<5%) | Low (<5%) | None (but metabolic side effects) |
Weight change | +2‑4kg (desired) | Neutral | Neutral | +5‑10kg (significant) |
Typical dose (adult) | 4‑20mg/day | 10mg/day | 10mg/day | 400‑800mg/day |
Metabolism | CYP3A4 | CYP3A4 (minor) | CYP3A4 | CYP3A4 |
Pregnancy safety | Category B (caution) | Category B | Category B | Category C (risk) |
Use the following decision matrix:
Because Periactin shares the CYP3A4 pathway, co‑administration with strong inhibitors (ketoconazole, erythromycin) can raise blood levels, increasing sedation. Conversely, inducers (rifampin, carbamazepine) may reduce efficacy.
Other notable interactions:
Always review a full medication list before starting Periactin or any alternative.
Understanding the broader pharmacological landscape helps you make smarter choices. The H1‑receptor antagonist class includes both first‑generation (Cyproheptadine, Diphenhydramine) and second‑generation (Cetirizine, Loratadine) drugs. First‑generations cross the blood‑brain barrier, causing sedation, while second‑generations are designed to stay peripheral.
The Serotonin receptor antagonist group includes Cyproheptadine (5‑HT2) and Ondansetron (5‑HT3). Though they target different receptors, both can affect appetite and nausea pathways.
For patients needing appetite improvement without antihistamine effects, Megestrol acetate offers a hormonal route, while Mirtazapine (an antidepressant with H1 blockade) is another off‑label option-each with its own risk profile.
Cyproheptadine has modest bronchodilatory effects, but it is not a first‑line asthma treatment. Doctors may prescribe it for allergy‑related rhinitis that aggravates asthma symptoms, but inhaled corticosteroids and bronchodilators remain the mainstay.
By blocking 5‑HT2 receptors, Cyproheptadine interferes with the brain’s satiety signals, leading to increased food intake. The effect is modest (2‑4kg) for most adults, but can be clinically useful for children or patients with cachexia.
Yes, the pediatric dose is 2mg once daily, up to a maximum of 4mg. Parents should watch for excessive sleepiness and ensure the child stays hydrated.
Cetirizine offers rapid relief with minimal sedation, making it preferable for daytime allergy control. Periactin provides similar relief but adds appetite stimulation and a higher chance of drowsiness, so it’s chosen when weight gain is also needed.
Co‑administration can increase the risk of serotonin syndrome because both affect serotonin pathways. If both are needed, a doctor will usually start at the lowest possible dose and monitor closely.
Symptoms include extreme drowsiness, confusion, rapid heartbeat, severe dry mouth, and in rare cases, seizures. Seek emergency medical care if you suspect an overdose.
Megestrol acetate is more potent for rapid weight gain in oncology settings, but it raises triglycerides and can suppress adrenal function. Oncologists balance these risks against the need for nutritional support.
Yes. Alcohol can amplify the sedative effects of first‑generation antihistamines like Periactin and Diphenhydramine. Second‑generation agents have a lower risk but still warrant caution.
Veronica Mayfair
Periactin sounds like a cool option if you need both sneezin' relief and a snack boost 😊
Rahul Kr
Looks like Periactin packs a double punch – antihistamine plus appetite aid. If sedation isn’t a deal‑breaker, it could be handy.